OM-002 is under clinical development by Intrinsic Medicine and currently in Phase II for Inflammatory Bowel Disease. According to GlobalData, Phase II drugs for Inflammatory Bowel Disease have a 37% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how OM-002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
OM-002 is under development for the treatment of pediatric and adult inflammatory bowel syndrome, coronavirus disease 2019 (COVID-19), frailty, constipation dominant form of irritable bowel syndrome (IBS-C) and diarrhea predominant form of IBS (IBS-D). It is administered by oral route. It was also under development for the treatment of acute and chronic inflammatory diseases.
Intrinsic Medicine overview
Intrinsic Medicine is a Pharmaceuticals and Healthcare company that produce medicine for chronic inflammatory diseases. The company is Headquartered in Seattle, Washington, The U.S.
For a complete picture of OM-002’s drug-specific PTSR and LoA scores, buy the report here.